levodopa/carbidopa

DRUG19 trials

Sponsors

Natsume Jun, Orion Corporation, Orion Pharma, The University of Texas Health Science Center, Houston, Novartis, Jaeb Center for Health Research

Conditions

AlbinismAmblyopiaCocaine AbuseCocaine DependenceCocaine-Related DisordersDravet syndrome(severe myoclonic epilepsy in infant) Dravet syndrome, severe myoclonic epilepsy in infantDyskinesiasHealthy

Phase 1

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

CompletedNCT01519284

Bial - Portela C S.A.Parkinson Disease

Start: 2009-11-30End: 2011-06-30Updated: 2015-08-20

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

CompletedNCT01533116

Bial - Portela C S.A.Parkinson Disease

Start: 2009-03-31End: 2010-03-31Updated: 2015-11-16

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

CompletedNCT01688089

Orion Corporation, Orion PharmaHealthy

Start: 2012-09-30End: 2014-09-30Updated: 2014-09-19

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

CompletedNCT01840423

Orion Corporation, Orion PharmaHealthy

Start: 2013-05-31End: 2014-12-31Updated: 2015-04-01

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

CompletedNCT02170376

Bial - Portela C S.A.Parkinson's Disease (PD)

Start: 2011-09-30End: 2012-01-31Updated: 2016-09-20

Phase 2

Medications for Stopping Cocaine Dependence and Preventing Relapse

CompletedNCT00218023

The University of Texas Health Science Center, HoustonCocaine Abuse, Cocaine-Related Disorders

Start: 2006-03-31End: 2012-04-30Updated: 2017-06-09

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

CompletedNCT00789672

Jaeb Center for Health ResearchAmblyopia

Start: 2009-01-31End: 2009-12-31Updated: 2016-07-13

Cognitive Remediation for Cocaine Dependence

CompletedNCT01393457

The University of Texas Health Science Center, HoustonCocaine Dependence

Start: 2011-06-30End: 2017-02-28Updated: 2018-03-29

Augmenting Language Therapy for Aphasia: Levodopa

CompletedNCT01429077

Shirley Ryan AbilityLabNonfluent Aphasia, Stroke

Start: 2007-10-31End: 2012-03-31Updated: 2013-12-25

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

CompletedNCT01568034

Bial - Portela C S.A.Parkinson's Disease

Start: 2009-04-30End: 2010-02-28Updated: 2015-01-12

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

CompletedNCT01568047

Bial - Portela C S.A.Parkinson's Disease

Start: 2010-02-28End: 2010-06-30Updated: 2015-12-24

Vision Response to Dopamine Replacement

TerminatedNCT01663935

University of Wisconsin, MadisonAlbinism, Oculocutaneous Albinism

Start: 2012-10-17End: 2018-04-12Updated: 2019-06-11

Fexofenadine as Adjuvant Therapy in Parkinson Disease

RecruitingNCT06785298

Tanta UniversityParkinson Disease

Start: 2024-12-10End: 2026-12-20Target: 46Updated: 2026-01-21

Phase 3

Levodopa for the Treatment of Residual Amblyopia

CompletedNCT01190813

Jaeb Center for Health ResearchAmblyopia

Start: 2010-09-30End: 2014-04-30Updated: 2016-06-02

Phase 4

Stalevo in Early Wearing-Off Patients

CompletedNCT00125567

Orion Corporation, Orion PharmaIdiopathic Parkinson's Disease

Start: 2005-08-31End: 2009-03-31Updated: 2009-06-22

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

CompletedNCT00391898

NovartisParkinson's Disease

Start: 2006-10-31End: 2008-06-30Updated: 2011-03-15

Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics

CompletedNCT00888186

Uppsala UniversityDyskinesias, Parkinson Disease

Start: 2008-02-29End: 2008-05-31Updated: 2009-04-27

Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors

CompletedNCT00906828

Uppsala UniversityParkinson Disease

Start: 2008-10-31End: 2009-11-30Target: 10Updated: 2010-01-18

3D gait analysis and L-DOPA in Dravet syndrome.

Active, not recruitingJPRN-jRCTs041190116

Natsume JunDravet syndrome(severe myoclonic epilepsy in infant) Dravet syndrome, severe myoclonic epilepsy in infant

Start: 2020-02-17Target: 20Updated: 2025-07-18